Liwei Dong
Impact in
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Immunology top 5%
Papers in
-
- RNA modifications and cancer 9
- Ubiquitin and proteasome pathways 7
-
- Cancer, Lipids, and Metabolism 9
- Cancer-related molecular mechanisms research 9
- Cancer, Hypoxia, and Metabolism 8
- Co-authors
- Hongyang Wang (40 shared papers)Yexiong Tan (40 shared papers)Yufei Pan (27 shared papers)Tianyi Jiang (26 shared papers)Lihui Xie (1 shared paper)Wenru Su (1 shared paper)Yushan Miao (1 shared paper)Wen Wen (1 shared paper)
- Journals
- Hepatology (6 papers)Cell Research (4 papers)Cancer Letters (4 papers)Cell Death and Disease (4 papers)Oncogene (2 papers)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Liwei Dong
99 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Cancer Research 686
- Immunology 546
- Molecular Biology 1.6k
- Infectious Diseases 425
- Hepatology 153
Countries citing papers authored by Liwei Dong
This map shows the geographic impact of Liwei Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwei Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwei Dong more than expected).
Fields of papers citing papers by Liwei Dong
This network shows the impact of papers produced by Liwei Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwei Dong. The network helps show where Liwei Dong may publish in the future.
Co-authors
The 25 scholars most cited alongside Liwei Dong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 102 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Immune cell profiling of COVID-19 patients in the recovery stageby single-cell sequencing Hit paper breakdown → | 2020 | 524 |
| 2 | 2016 | 127 | |
| 3 | 2007 | 114 | |
| 4 | 2015 | 111 | |
| 5 | 2014 | 102 | |
| 6 | 2013 | 75 | |
| 7 | 2015 | 73 | |
| 8 | 2011 | 67 | |
| 9 | 2009 | 61 | |
| 10 | 2013 | 61 | |
| 11 | 2022 | 59 | |
| 12 | 2011 | 58 | |
| 13 | 2011 | 58 | |
| 14 | 2016 | 54 | |
| 15 | 2011 | 52 | |
| 16 | 2013 | 51 | |
| 17 | 2023 | 51 | |
| 18 | 2015 | 51 | |
| 19 | 2015 | 49 | |
| 20 | 2023 | 49 |
About Liwei Dong
Liwei Dong is a scholar working on Molecular Biology, Cancer Research, Surgery, Oncology and Immunology, having authored 102 papers that have together received 3.2k indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers), Cancer, Lipids, and Metabolism (9 papers), RNA modifications and cancer (9 papers), Cancer-related molecular mechanisms research (9 papers), Cancer, Hypoxia, and Metabolism (8 papers), Peptidase Inhibition and Analysis (8 papers), Ubiquitin and proteasome pathways (7 papers) and Autophagy in Disease and Therapy (6 papers). The work is most often cited by research in Cancer Research (686 citations), Immunology (546 citations), Molecular Biology (1.6k citations), Infectious Diseases (425 citations) and Hepatology (153 citations). Liwei Dong has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Hongyang Wang, Yexiong Tan, Yufei Pan, Tianyi Jiang, Lihui Xie, Wenru Su, Yushan Miao, Wen Wen, Yingfeng Zheng and Jiantao Dong. Their work appears in journals such as Hepatology, Cell Research, Cancer Letters, Cell Death and Disease and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.